Pay in 4 interest-free payments of $22.50 Learn more
Ships within 48 hours · Estimated delivery Aug 6 - Aug 11
A phase I first-in-human trial of bardoxolone methyl in patients with advanced solid tumors and lymphomas
Formula: C16H18Cl2NO5P
5740/jaoacint
InChi: InChI=1S/C25H29FN4O5/c1-27-25(32)35-22-15-34-21-7-6-18(29-8-10-30(11-9-29)19-13-33-14-19)12-20(21)23(22)28-24(31)16-2-4-17(26)5-3-16/h2-7
AZ 628 Size:Solid 2 mg A phase I first-in-human trialAZ 628 is a selective, orally available Raf inhibitor with excellent pharmacokinetic properties and robust tumor growth inhibition in xenograft studies ( (IC50 values are 29, 34 and 105 nM for c Raf1, B RafV600E and wild type B Raf, respectively). AZ 628 inhibits growth, and induces cell cycle arrest and apoptosis in colon and melanoma cell lines with the B RafV600E mutation. Product information CAS Number: 878739 06 1 Molecular Weight: 451. 52
US$ 39.95
US$ 129.44
US$ 85.95
US$ 19.00
US$ 18.00
US$ 25.95